1-4 of 4
Zhi-Hua Cui
Close
Sort by
Journal Articles

Evaluation of Idelalisib with B-Cell Receptor or Orthogonal Pathway Inhibitors in Diffuse Large B-Cell Lymphoma Cell Lines in Vitro and In Vivo

Sarah Meadows, Anella Yahiaoui, Rick Sorensen, Zhi-Hua Cui, PhD, Robert Brockett, Kathleen S Keegan, PhD, Stacey Tannheimer
Journal: Blood
Blood (2016) 128 (22): 1845.
https://doi.org/10.1182/blood.V128.22.1845.1845
Published: 2016
Journal Articles

Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice

Junliang Pan, Tongyao Liu, Ji-Yun Kim, Daguang Zhu, Chandra Patel, Zhi-Hua Cui, Xin Zhang, James O. Newgren, Aaron Reames, Dodie Canivel, Gary Jesmok, Glenn F. Pierce, Jurg M. Sommer, Haiyan Jiang
Journal: Blood
Blood (2009) 114 (13): 2802–2811.
https://doi.org/10.1182/blood-2009-03-212423
Published: 2009
Journal Articles

A Pharmacologic Evaluation of BAY 79-4980 (Liposome-Formulated Kogenate® FS) in the Hemophilia A Mouse.

Gary Jesmok, Zhi-Hua Cui, Deogracias Canivel, Michael Fournel, Glenn Pierce, Kyle Landskroner
Journal: Blood
Blood (2006) 108 (11): 4003.
https://doi.org/10.1182/blood.V108.11.4003.4003
Published: 2006
Journal Articles

Evaluation of PEG-FVIII Molecules with Prolonged Half-Lives in a Murine FVIII-Dependent Bleeding Model.

Kyle A. Landskroner, Zhi-Hua Cui, James Newgren, Michael Fournel, Glenn F. Pierce, Gary J. Jesmok
Journal: Blood
Blood (2006) 108 (11): 1624.
https://doi.org/10.1182/blood.V108.11.1624.1624
Published: 2006